Earnings Feed
Start Free
Revance Therapeutics, Inc.·4

Feb 17, 8:21 PM ET

Revance Therapeutics, Inc. 4

4 · Revance Therapeutics, Inc. · Filed Feb 17, 2016

Insider Transaction Report

Form 4
Period: 2016-02-12
Revance Therapeutics, Inc.RVNC
BYRNES ROBERT F
Director
Transactions
  • Exercise/Conversion

    Common Stock

    2016-02-12$2.55/sh+5,333$13,599→ 10,999 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2016-02-12−4,000→ 0 total
    Exercise: $6.60Exp: 2016-09-18→ Common Stock (4,000 underlying)
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2016-02-12−1,666→ 0 total
    Exercise: $2.55Exp: 2020-07-20→ Common Stock (1,666 underlying)
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2016-02-12−5,333→ 0 total
    Exercise: $2.55Exp: 2018-04-29→ Common Stock (5,333 underlying)
  • Exercise/Conversion

    Common Stock

    2016-02-12$6.60/sh+4,000$26,400→ 4,000 total
  • Exercise/Conversion

    Common Stock

    2016-02-12$2.55/sh+1,666$4,248→ 5,666 total
Holdings

  • Common Stock

    (indirect: By Trust)
    2,666
Footnotes (3)
  • [F1]The Option was fully vested as of September 19, 2010.
  • [F2]The Option was fully vested as of January 1, 2014.
  • [F3]The Option was fully vested as of January 1, 2012.

Documents

1 file
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION